Day One Biopharmaceuticals (DAWN) Short Interest Ratio & Short Volume

Short interest is the volume of Day One Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 11,690,000 shares of DAWN short. 15.66% of Day One Biopharmaceuticals' shares are currently sold short. Learn More on Day One Biopharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DAWN shares currently have a short interest ratio of 9.0. Learn More on Day One Biopharmaceuticals's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Day One Biopharmaceuticals: Caption Management LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 15.66% of Day One Biopharmaceuticals' floating shares are currently sold short.

Day One Biopharmaceuticals saw a decline in short interest in June. As of June 30th, there was short interest totaling 11,690,000 shares, a decline of 7.3% from the previous total of 12,610,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Day One Biopharmaceuticals currently has issued a total of 101,360,000 shares. Some of Day One Biopharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Day One Biopharmaceuticals currently has a public float of 74,660,000 shares.

15.66% of Day One Biopharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Day One Biopharmaceuticals: Ultragenyx Pharmaceutical Inc. (7.63%), Alvotech (1.63%), Amneal Pharmaceuticals, Inc. (4.56%), Mirum Pharmaceuticals, Inc. (15.35%), Catalyst Pharmaceuticals, Inc. (7.48%), Arrowhead Pharmaceuticals, Inc. (9.55%), ImmunityBio, Inc. (37.57%), Organon & Co. (6.15%), Apellis Pharmaceuticals, Inc. (22.25%), Xenon Pharmaceuticals Inc. (5.92%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

Short selling DAWN is an investing strategy that aims to generate trading profit from Day One Biopharmaceuticals as its price is falling. DAWN shares are trading up $0.37 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Day One Biopharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DAWN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DAWN, twice per month. The most recent reporting period available is June, 30 2025.